NCT03122834Completed
Effect of Genetic Polymorphism on the Clinical Outcome of Patients With Heart Failure
Effect of Genetic Polymorphism on the Clinical Outcome, Echocardiographic Parameters and Cardiac Biomarkers of Patients With Heart Failure
Source: ClinicalTrials.gov · Last updated 20 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Heart failure (HF) is one the most common cause of hospitalization and represents the end stage of a variety of heart conditions; it is associated with significant morbidity and mortality.The pathophysiology of HF is centered on increased activity in the adrenergic and renin-angiotensin-aldosterone systems (RAAS), which leads to vasoconstriction and fluid restriction with further deleterious effect on cardiac function. Β-blockers, angiotensin converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs) and aldosterone antagonists reduce activity in these pathways and have shown prognostic benefit, thus are the foundation of HF therapy.There is a growing body of evidence that variation in proteins within the sympathetic axis and RAAS influence drug response thus increasingly pharmacogenetics of HF research is being sought as a way to optimize HF treatment and advance new drug development in this area.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 246 (actual)
- First submitted
- 14 Apr 2017
- Start date
- 15 Apr 2020
- Primary completion date
- 10 Apr 2024
- Lead sponsor
- Ain Shams University
- Diseases
- Heart failure
- NCT number
- NCT03122834
What you commit to
- Study type: Observational
- Participants enrolled: 246
- From 15 Apr 2020 to the primary completion date, 10 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who received previous treatment with Spironolactone / Eplerenone.
- Sig CAD, CABG, PCI, or valve surgery within 3 months.
Other
- Contraindication to SGLT2i.
- Contraindication to Spironolactone / Eplerenone.
- Mild-to-severe valvular stenosis or severe (grade III/IV) valvular regurgitation
- Pregnant or nursing women.
Who the study is looking for
- Heart failure patients NYHA class II to IV.
- Left ventricular ejection fraction (LVEF) \< 45%
- Written informed consent of the subject to participate in the study.
- Newly diagnosed patients who will be treated with BBs and ACEIs/or ARBs.
- Patients who are candidate for add-on treatment with Spironolactone / Eplerenone.
- Age of 18 years to 80 years.
Age in the registry: 18 years to 80 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Heart Institute Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.